Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.46 |
| ▸ | MMP3 | P08254 | 4/20 | 0.46 |
| ▸ | MMP7 | P09237 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP14 | P50281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9067396 | 0.82 | MMP1 (0.51) | MMP1MMP3MMP2MMP9MMP14 | |
| SCHEMBL7053125 | 0.78 | MEN1 (0.39) | MEN1KMT2AMAPK1 | |
| SCHEMBL6413994 | 0.78 | MEN1 (0.39) | MEN1KMT2AMAPK1 | |
| SCHEMBL7451414 | 0.74 | MMP1 (0.71) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7763149 | 0.73 | MMP1 (0.61) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL6806856 | 0.71 | MMP1 (0.69) | MMP1MMP3MMP7MEN1KMT2A | |
| SCHEMBL7758531 | 0.71 | MMP1 (0.69) | MMP1MMP3MMP7MEN1KMT2A | |
| SCHEMBL7385098 | 0.70 | SMN1; SMN2 (0.52) | MEN1KMT2AMAPK1 | |
| SCHEMBL7763578 | 0.67 | MMP1 (0.58) | MMP1MMP3MMP7MMP2MMP9 | |
| SCHEMBL7374287 | 0.65 | MMP1 (0.58) | MMP1MMP3MMP7MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |